ダウンロード数: 846
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
j.ctrv.2010.05.004.pdf | 436.39 kB | Adobe PDF | 見る/開く |
タイトル: | Second-line chemotherapy for small-Cell Lung Cancer (SCLC). |
著者: | Kim, Young Hak Mishima, Michiaki |
著者名の別形: | 金, 永学 |
キーワード: | Small-cell lung cancer Relapsed Chemotherapy Second-line Sensitive Refractory |
発行日: | Apr-2011 |
出版者: | Elsevier Ltd |
誌名: | Cancer treatment reviews |
巻: | 37 |
号: | 2 |
開始ページ: | 143 |
終了ページ: | 150 |
抄録: | Although small-cell lung cancer (SCLC) generally shows an excellent response to initial chemotherapy, most patients finally relapse and salvage chemotherapy is considered. Usually, the response to salvage chemotherapy significantly differs between sensitive and refractory relapse. Sensitive relapse is relatively chemosensitive and re-challenge with the same drugs as used in the initial chemotherapy has been used historically, while refractory relapse is extremely chemo-resistant and its prognosis has been abysmal. To date, a number of clinical trials have been carried out for relapsed SCLC; however, the number of randomized trials is quite limited. At present, topotecan is the only drug approved by the US Food and Drug Administration for relapsed SCLC, and is considered the standard second-line chemotherapy in many countries. More recently, amrubicin has also shown more favorable antitumor activity, and is the most promising at present. Unfortunately, targeted agents have failed to demonstrate effectiveness for SCLC. Better understanding of the molecular mechanisms is clearly needed. |
著作権等: | © 2010 Elsevier Ltd この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。 This is not the published version. Please cite only the published version. |
URI: | http://hdl.handle.net/2433/137220 |
DOI(出版社版): | 10.1016/j.ctrv.2010.05.004 |
PubMed ID: | 20580163 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。